Nicole Junkermann on Britain's £1 Billion Scale-Up Fund: An August 2026 Outlook

An idea about backing homegrown science moved quietly through the news this past week, and for once the money involved was the least interesting thing about it.

Every so often a proposal appears that says less about a single year than about a change of mind. This week brought one of those. The plan, still taking shape, is for a proposed new fund, drawn together by the country's long-term savings institutions alongside a national investment effort, and aimed at Britain's fast-growing science and technology companies. The purpose is simple to state and surprisingly hard to achieve: to help these companies grow up at home rather than being sold or moved abroad the moment they begin to matter. Nicole Junkermann has spent much of her working life around young companies of exactly this kind, and she reads the news less as a headline about money and more as a signal about confidence.

Britain has never had a shortage of good ideas. What it has too often lacked is the patient money to carry those ideas through their most awkward and expensive years, the long stretch between a clever prototype and a company large enough to stand on its own. It is a stage that founders know well and dread a little. A promising business reaches the point where it needs serious capital to scale, and finds that the cheque it requires is easier to raise overseas than at home. Talent follows the money, and a company that might have become a national asset quietly becomes someone else's. A fund designed to close that gap is, in effect, a decision to stop losing at the final hurdle.

Why homegrown scale matters

There is a temptation to treat all of this as an accountant's concern, a question of where a company is registered and whose portfolio it sits in. It is far more than that. When a business scales where it was born, it keeps its best jobs nearby, it trains a generation of people in how hard things are actually built, and it becomes an anchor that smaller companies can gather around. The knowledge stays in the room. The graduates who might have moved overseas find a reason to stay. Over time a single company that reaches real size can seed a whole cluster, and clusters are how countries end up genuinely good at things. None of this is visible in a single quarter. All of it compounds.

Nicole Junkermann tends to be optimistic about efforts like this for a straightforward reason. It is the behaviour of a country that has decided to back itself. You can spend a great deal of energy cataloguing what a place gets wrong, and there is always a list. It is rarer, and far more useful, to notice the moment a country chooses to lean into something it is genuinely good at. Britain is good at science. For its size it produces a striking share of the research that others go on to build upon, and around a handful of its cities sit laboratories and young companies that have been quietly compounding for years. Deciding to fund the leap from promising to permanent is simply good sense.

Patience is the point

The most encouraging thing about a fund of this shape is the time horizon buried inside it. Money drawn from long-term savings is, by its nature, in no hurry. It can wait out the years that real science demands, the testing and the setbacks and the slow grind from a good result in a laboratory to something that changes an ordinary life. Impatient capital can only fund what is already obvious. The genuinely new, the treatment that takes a decade or the technology that takes a generation, depends on someone willing to wait. It is the same slow, long-dated conviction that runs through what a large commitment to British life sciences tells us about the country's future, and the quiet discipline explored in patient capital. Money that is prepared to be patient tends to matter far more than a larger sum in a hurry.

None of this is settled by an announcement, and Nicole Junkermann would be the first to say so. A fund is a tool, not a triumph. Its value will be decided by the founders it backs, by institutions steady enough to leave those founders alone long enough to let the work happen, and by a wider public that stays curious about what is being attempted in its name. Money on its own builds nothing. What it can do is take some of the fear out of ambition, and give a good idea the room to become a large one without having to leave the country to do it. That is a modest promise, and a genuinely hopeful one.

A quietly hopeful direction

So what does a proposed new fund for high-growth companies really tell us? Not that the road is smooth, and not that everything attempted will succeed. It tells us that the direction of travel is towards backing homegrown invention rather than watching it drift away, and that the appetite to build at home is returning. Any results will arrive slowly, in companies that reach a size no one quite expected, and much of the best of it will be invisible until it becomes ordinary. The future rarely announces itself. More often it is patiently supported, years ahead of time, by people willing to wait for it.

This article is general reflection and commentary. It is not financial or investment advice.

More from Nicole Junkermann

For more from Nicole Junkermann, read the full profile of Nicole Junkermann, or visit the Notebook and the Writing Desk.

← Back to the blog